In search of potent β3-adrenergic receptor agonists, a series of novel substituted 1, 2, 3, 4- tetrahydroquinolin-6-yloxypropanes has been synthesized and evaluated for their β3- adrenergic receptor agonistic activity (ranging from− 17.73% to 90.64% inhibition at 10μM) using well established Human SK-N-MC neuroblastoma cells model. Four molecules viz. 11, 15, 22 and 23 showed β3-AR agonistic IC50 value of 0.55, 0.59, 1.18 and 1.76 μM, ...